EXPRESS MAIL CERTIFICATE

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. § 1.10 on the date indicated below and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231

Typed or Printed Name	Dave Glisson	Express Mail No.	EL 563 386 425 US
Signature	*Dave Glisson*	Date	September 5, 2000

SECOND PRELIMINARY AMENDMENT Address to: Assistant Commissioner for Patents Washington, D.C. 20231	Attorney Docket	SHIM-006
	First Named Inventor	Takuya Tamatani et al.
	Application Number	09/582.337
	Int'l. Filing Date	December 16, 1998
	Group Art Unit	Unassigned
	Examiner Name	Unassigned
	Title	**Monoclonal Antibody Against Connective Tissue Growth Factor and Medicinal Uses Thereof**

Sir:

This is a preliminary amendment to the patent application identified above. Prior to examination of the subject application, please enter the following amendments to the specification and claims:

AMENDMENTS

IN THE CLAIMS:

Please **cancel** claims 83-103 and **add** new claims 104-154 as follows:

104.   (New) A monoclonal antibody of a portion thereof, comprising a property selected from the group consisting:

(a) reactive to human, mouse and rat connective tissue growth factors (CTGFs);

(b) reactive to both human and mouse CTGFs but not reactive to rat CTGF;

(c) reactive to both mouse and rat CTGFs but not reactive to human CTGF;

(d) reactive to rat CTGF;

(e) inhibiting binding of human CTGF to human kidney-derived fibroblast cell line 293-T (ATCC CRL1573), or the binding of mouse CTGF to said cell line 293-T;

(f) inhibiting binding of human CTGF to any cells of rat kidney-derived fibroblast cell line NRK-49F (ATCC CRL-1570), human osteosarcoma-derived cell line MG-63 (ATCC CRL-1427), or human lung-derived fibroblasts;

(g) inhibiting cell proliferation of rat kidney-derived fibroblast cell line NRK-49F (ATCC CRL-1570) induced by stimulus with human or mouse CTGF;